Skip to content
Cancer Institute NSW sites
eviQ Education
Learning resources for cancer staff
opens in a new tab or window
Cancer Institute NSW
NSW cancer control agency
opens in a new tab or window
Patient Information
Practical advice about cancer
opens in a new tab or window
Canrefer
Find a cancer specialist
opens in a new tab or window
BreastScreen NSW
Detect breast cancer early
opens in a new tab or window
Cervical Screening NSW
Cervical Screening NSW
opens in a new tab or window
iCanQuit
Learn how to quit smoking
opens in a new tab or window
Log in
Register
Search
Search
Log in
Register
Search
Main menu Toggle menu collaspe
Search eviQ
Close
Search
Search
Home
Home
Cancer genetics
Adult
Genetic testing for heritable pathogenic variants
Genetic testing using cancer gene panels
Risk management
Paediatric
Genetic testing for heritable pathogenic variants
Genetic testing using cancer gene panels
Risk management
Referral guidelines
Consumer information
Resources
Haematology and BMT
Leukaemias
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Acute promyelocytic leukaemia
Chronic lymphocytic leukaemia
Chronic myeloid leukaemia
Hairy cell leukaemia
Myelodysplastic disorders
Lymphoma
Hodgkin lymphoma
Burkitt lymphoma
Mantle cell lymphoma
NK-cell and T-cell lymphoma
Other B-cell lymphoma
Primary CNS lymphoma
Waldenstrom macroglobulinaemia
Multiple myeloma
Blood and marrow transplant
Mobilisation
Allogeneic
Autologous
GVHD prophylaxis
Cellular therapies
Medical oncology
Breast
Neoadjuvant/Adjuvant
Metastatic
Colorectal
Adjuvant and neoadjuvant
Metastatic
Anal
Rectal
Gynaecological
Cervical
Endometrial
Gestational trophoblastic disease
Ovarian
Vulval
Head and neck
Definitive chemoradiation
Induction chemotherapy
Nasopharyngeal
Post operative chemoradiation
Recurrent or metastatic
Salivary gland
Thyroid
Neurological
Glioma
Respiratory
Mesothelioma
Non small cell lung cancer - Adjuvant/neoadjuvant
Non small cell lung cancer - Advanced/metastatic
Small cell lung cancer
Sarcoma
Soft tissue sarcoma
Bone sarcoma
Skin
Melanoma neoadjuvant/adjuvant
Melanoma metastatic
Non-melanoma
Upper gastrointestinal
Gastric and oesophageal adjuvant and neoadjuvant
Gastric and oesophageal metastatic
Gastrointestinal stromal cell tumours
Hepatic
Neuroendocrine
Pancreas and biliary
Urogenital
Adrenocortical
Bladder and Urothelial
Prostate
Renal
Testicular
Penile
Rare cancers
Colorectal
Gynaecological
Head and neck
Melanoma
Neurological
Respiratory
Sarcoma
Upper gastrointestinal
Urogenital
Tumour-agnostic
Tumour-agnostic
Radiation oncology
Breast
Colorectal
Gynaecological
Haematology
Head and neck
Neurological
Palliative
Respiratory
Upper gastrointestinal
Urogenital
Bladder
Prostate
Kidney and adrenal
Skin
Stereotactic
Clinical resources
eviQ calculators
Aboriginal health workers
ADDIKD guideline
Administration of anti-cancer drugs
Assessment tools
BMT & cellular therapies
Central venous access devices (CVADs)
Day of Treatment Assessment
Extravasation
Pumps
Health professional fact sheets
Oncological emergencies
Radiation oncology
Assessment tools
Cardiac implantable electronic devices
Contrast administration
Radiation-induced dermatitis
Side effect and toxicity management
Side effect and toxicity management
Cardiovascular
Gastrointestinal
General
Genitourinary
Gynaecological
Haematological
Hair, skin and nails
Immunological
Neurological and sensory
Oropharyngeal
Prophylaxis and treatment
Reproductive
Respiratory
Telephone triage toolkit
Patients and carers
Anticancer drug treatments
Radiation therapy treatments
Cancer genetics information sheets
Patient information sheets
At home
Cancer type specifics
Complementary and alternative medicines
Eating and drinking
Fertility, sex, pregnancy and breastfeeding
Treating cancer with medicines
How you have anticancer medicine treatment
Treating cancer with radiation therapy
Managing side effects
Vaccinations
Your family and friends
Patient information in other languages
عربى (Arabic)
简 (Simplified Chinese)
繁 (Traditional Chinese)
Français (French)
Ελληνικά (Greek)
Italiano (Italian)
한국어 (Korean)
Español (Spanish)
Tiếng Việt (Vietnamese)
Македонски (Macedonian)
ไทย (Thai)
Patient information videos
Cancer Institute NSW sites
eviQ Education
Learning resources for cancer staff
opens in a new tab or window
Cancer Institute NSW
NSW cancer control agency
opens in a new tab or window
Patient Information
Practical advice about cancer
opens in a new tab or window
Canrefer
Find a cancer specialist
opens in a new tab or window
BreastScreen NSW
Detect breast cancer early
opens in a new tab or window
Cervical Screening NSW
Cervical Screening NSW
opens in a new tab or window
iCanQuit
Learn how to quit smoking
opens in a new tab or window
Home
Haematology and BMT
Leukaemias
Acute myeloid leukaemia
33 results
Search
Acute myeloid leukaemia azacitidine
Acute myeloid leukaemia azacitidine and ivosidenib
Acute myeloid leukaemia azacitidine and venetoclax
Acute myeloid leukaemia azacitidine maintenance oral
Acute myeloid leukaemia consolidation 5-2 Ida (cytarabine and iDArubicin)
Acute myeloid leukaemia consolidation cytarabine (age 60 years and over)
Acute myeloid leukaemia consolidation cytarabine (age under 60 years)
Acute myeloid leukaemia FLAG (fludarabine cytarabine and filgrastim)
Acute myeloid leukaemia FLAG-Ida (fludarabine cytarabine iDArubicin and filgrastim)
Acute myeloid leukaemia FLAG-Ida-Ven overview
Acute myeloid leukaemia gilteritinib
Acute myeloid leukaemia induction 7-3 (cytarabine and DAUNOrubicin)
Acute myeloid leukaemia induction 7-3 GO (cytarabine, DAUNOrubicin and gemtuzumab ozogamicin) MRC and consolidation cytarabine overview
Acute myeloid leukaemia induction 7-3 GO and consolidation ALFA overview
Acute myeloid leukaemia induction 7-3 Ida (cytarabine and iDArubicin)
Acute myeloid leukaemia induction/consolidation/maintenance with midostaurin overview
Acute myeloid leukaemia liposomal DAUNOrubicin and cytarabine overview
Acute myeloid leukaemia low dose cytarabine
Acute myeloid leukaemia low dose cytarabine and venetoclax
Acute myeloid leukaemia STIMULus (low dose cytarabine and tioguanine) overview
Decitabine and cedazuridine oral
Acute myeloid leukaemia consolidation 5-2 (cytarabine and DAUNOrubicin) SUPERSEDED
Acute myeloid leukaemia HAM (cytarabine and mitozantrone) SUPERSEDED
Acute myeloid leukaemia induction 7-3 high dose DAUNOrubicin (cytarabine and DAUNOrubicin) SUPERSEDED
Acute myeloid leukaemia induction/consolidation (Lowenberg) SUPERSEDED
Acute myeloid leukaemia consolidation 5-2-5 modified (cytarabine IDArubicin and etoposide) DISCONTINUED
Acute myeloid leukaemia consolidation HiDAC (cytarabine) 1,2,3 DISCONTINUED
Acute myeloid leukaemia consolidation HiDAC (cytarabine) 1,3,5 DISCONTINUED
Acute myeloid leukaemia consolidation IDAC (cytarabine) DISCONTINUED
Acute myeloid leukaemia consolidation little IcE 5 days (iDArubicin cytarabine and etoposide) DISCONTINUED
Acute myeloid leukaemia induction 7-3 (cytarabine and DAUNOrubicin) DISCONTINUED
Acute myeloid leukaemia induction 7-3-7 modified (cytarabine iDArubicin and etoposide) DISCONTINUED
Acute myeloid leukaemia induction big ICE 7 Days (iDArubicin cytarabine and etoposide) DISCONTINUED
Title
Content